- Home
- BMGL vs ZURA Comparison
BMGL vs ZURA Comparison
Compare BMGL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- ZURA
- Stock Information
- Founded
- BMGL 2001
- ZURA 2022
- Country
- BMGL Singapore
- ZURA United States
- Employees
- BMGL N/A
- ZURA N/A
- Industry
- BMGL
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMGL
- ZURA Health Care
- Exchange
- BMGL NYSE
- ZURA Nasdaq
- Market Cap
- BMGL 78.3M
- ZURA 76.6M
- IPO Year
- BMGL 2025
- ZURA N/A
- Fundamental
- Price
- BMGL $6.08
- ZURA $1.01
- Analyst Decision
- BMGL
- ZURA Buy
- Analyst Count
- BMGL 0
- ZURA 7
- Target Price
- BMGL N/A
- ZURA $14.33
- AVG Volume (30 Days)
- BMGL 11.2M
- ZURA 520.6K
- Earning Date
- BMGL 01-01-0001
- ZURA 05-08-2025
- Dividend Yield
- BMGL N/A
- ZURA N/A
- EPS Growth
- BMGL 16.23
- ZURA N/A
- EPS
- BMGL 0.09
- ZURA N/A
- Revenue
- BMGL $7,428,776.00
- ZURA N/A
- Revenue This Year
- BMGL N/A
- ZURA N/A
- Revenue Next Year
- BMGL N/A
- ZURA N/A
- P/E Ratio
- BMGL $64.62
- ZURA N/A
- Revenue Growth
- BMGL 3.32
- ZURA N/A
- 52 Week Low
- BMGL $0.91
- ZURA $0.97
- 52 Week High
- BMGL $7.18
- ZURA $5.56
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- ZURA 35.69
- Support Level
- BMGL N/A
- ZURA $0.99
- Resistance Level
- BMGL N/A
- ZURA $1.06
- Average True Range (ATR)
- BMGL 0.00
- ZURA 0.08
- MACD
- BMGL 0.00
- ZURA -0.01
- Stochastic Oscillator
- BMGL 0.00
- ZURA 7.17
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.